Exelixis Will Proceed With Development Of XL999 In NSCLC Based On Efficacy Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Clinical trial will initiate in the patient population this summer, with monitoring of cardiovascular events.
You may also be interested in...
GlaxoSmithKline Passes On Option For Exelixis’ XL647 Lung Cancer Candidate
Exelixis says it will move aggressively to advance EGFR candidate into pivotal trials in first half of 2008 for NSCLC and Phase II for other cancers.
GlaxoSmithKline Passes On Option For Exelixis’ XL647 Lung Cancer Candidate
Exelixis says it will move aggressively to advance EGFR candidate into pivotal trials in first half of 2008 for NSCLC and Phase II for other cancers.
Despite Enrollment Suspension, Exelixis Optimistic On XL999
Tyrosine kinase inhibitor is one of a dozen compounds GlaxoSmithKline can option.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: